Journal article
Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain
AD Cook, J Pobjoy, S Sarros, DC Lacey, JA Hamilton, S Steidl, M Dürr
Annals of the Rheumatic Diseases | Published : 2012
Abstract
Objectives: Better therapies are needed for inflammatory pain. In arthritis the relationship between joint pain, inflammation and damage is unclear. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is important for the progression of a number of inflammatory/autoimmune conditions including arthritis; clinical trials targeting its action in rheumatoid arthritis are underway. However, its contribution to inflammatory and arthritic pain is unknown. The aims of this study were to determine whether GM-CSF controls inflammatory and/or arthritic pain. Methods: A model of inflammatory pain (complete Freund's adjuvant footpad), as well as two inflammatory arthritis models, were induced in GM..
View full abstractGrants
Funding Acknowledgements
[ "This work was supported by grants from Morphosys AG and the National Health and Medical Research Council (NHMRC), and by a NHMRC Senior Principal Research Fellowship (JAH).", "SSt is a full-time employee of MorphoSys AG, Germany. JAH has received consulting fees from MorphoSys AG, Germany (less than US$10 000 a year). The University of Melbourne has licensed to MorphoSys AG, Germany, patented technology relating to therapeutically targeting granulocyte-macrophage colony-stimulating factor, for which licensing fees and milestone payments have been made. The other authors state no conflict of interests." ]